Cargando…

Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors

Selective cyclooxygenase-2 (COX-2) inhibitors were developed to reduce the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents. However, COX-2 inhibitors decrease prostacyclin production and may disrupt the normal homeostatic balance, leading to a prothrombotic state and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Debabrata, Topol, Eric J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC154429/
https://www.ncbi.nlm.nih.gov/pubmed/12716442
http://dx.doi.org/10.1186/ar609
_version_ 1782120748915097600
author Mukherjee, Debabrata
Topol, Eric J
author_facet Mukherjee, Debabrata
Topol, Eric J
author_sort Mukherjee, Debabrata
collection PubMed
description Selective cyclooxygenase-2 (COX-2) inhibitors were developed to reduce the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents. However, COX-2 inhibitors decrease prostacyclin production and may disrupt the normal homeostatic balance, leading to a prothrombotic state and offsetting the potential gastrointestinal benefits. Available clinical data and basic biological studies raise significant concern about the potential prothrombotic effect of this class of drugs. Two recent studies with a newer, more selective COX-2 inhibitor have added to the already existing concern about the cardiovascular safety of these agents. The widespread use of these agents mandates prospective, randomized evaluation of the cardiovascular safety of COX-2 inhibitors.
format Text
id pubmed-154429
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1544292003-05-07 Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors Mukherjee, Debabrata Topol, Eric J Arthritis Res Ther Commentary Selective cyclooxygenase-2 (COX-2) inhibitors were developed to reduce the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents. However, COX-2 inhibitors decrease prostacyclin production and may disrupt the normal homeostatic balance, leading to a prothrombotic state and offsetting the potential gastrointestinal benefits. Available clinical data and basic biological studies raise significant concern about the potential prothrombotic effect of this class of drugs. Two recent studies with a newer, more selective COX-2 inhibitor have added to the already existing concern about the cardiovascular safety of these agents. The widespread use of these agents mandates prospective, randomized evaluation of the cardiovascular safety of COX-2 inhibitors. BioMed Central 2003 2002-10-28 /pmc/articles/PMC154429/ /pubmed/12716442 http://dx.doi.org/10.1186/ar609 Text en Copyright © 2003 BioMed Central Ltd
spellingShingle Commentary
Mukherjee, Debabrata
Topol, Eric J
Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
title Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
title_full Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
title_fullStr Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
title_full_unstemmed Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
title_short Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
title_sort cox-2: where are we in 2003? - cardiovascular risk and cox-2 inhibitors
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC154429/
https://www.ncbi.nlm.nih.gov/pubmed/12716442
http://dx.doi.org/10.1186/ar609
work_keys_str_mv AT mukherjeedebabrata cox2wherearewein2003cardiovascularriskandcox2inhibitors
AT topolericj cox2wherearewein2003cardiovascularriskandcox2inhibitors